It's How Medicine Should Be®


French German Italian Portuguese Russian

CMV-Seropositive Recipients Undergoing Hematopoietic Cell Transplant Treatment Study

Clinical Trial Title: 
A randomized, double-blind, placebo-controlled, phase 3 trial to evaluate the protective efficacy and safety of a therapeutic vaccine, ASP0113, in cytomegalovirus (CMV)-seropositive recipients undergoing allogeneic, hematopoietic cell transplant (HCT)
Clinical Trial Protocol ID: 
Clinical Trial Investigator Name: 
John J. Maciejewski, MD, PhD
Clinical Trial Area: 
Blood Disorders and Hematologic Cancers
Contact Phone: 
(312) 563-3347
Contact Name: 
Deborah Pach, RN